| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 154, Issue 12 6466-6474, Copyright © 1995 by American Association of Immunologists
ARTICLES |
H Tahara, L Zitvogel, WJ Storkus, HJ Zeh 3rd, TG McKinney, RD Schreiber, U Gubler, PD Robbins and MT Lotze
Department of Surgery, School of Medicine, Pittsburgh Cancer Institute, University of Pittsburgh, PA 15213, USA.
Our recent studies using IL-12 protein or fibroblasts genetically engineered to secrete IL-12 have demonstrated profound antitumor effects of IL-12 in murine models. The antitumor effects of local, high level IL-12 expression were examined using a retroviral vector, which can express both IL-12 subunits (p35 and p40) and the neomycin phosphotransferase (Neo)-marker gene from a polycistronic message utilizing internal ribosome entry site sequences. All animals intradermally (i.d.) receiving MCA207 murine sarcoma cell line nontransfected or Neo-transfected had progressively growing tumor, whereas all animals injected with MCA207 transfected with IL-12 were tumor free and were subsequently determined to be immune to a rechallenge of nontransfected MCA207 i.d. Similar results were obtained in experiments using the poorly immunogenic MCA102 murine sarcoma cell line. The inoculation of live MCA207-IL-12 tumor cells also caused the regression of contralateral nontransfected MCA207 inoculated either at the same time (80% protection) or up to 3 days before (33% protection) to the therapeutic tumor inoculation. In vivo depletion studies suggest that NK cells and IFN-gamma play important roles in the development of the early phase of the antitumor response, but that T cells (both CD4+ and CD8+) play the major role in the subsequent events, leading to long- term immunity. The potent antitumor effects observed for paracrine gene- delivered administration of IL-12 have thus been confirmed for multiple tumor cell types and in multiple murine strains. We believe that these results support the feasibility of IL-12 gene therapy for the treatment of human cancer.
This article has been cited by other articles:
|
|
 |
|
  J M Peron, C Bureau, P Gourdy, H Lulka, A Souque, B Calippe, J Selves, T Al Saati, J Bernad, P Cordelier, et al. Treatment of experimental murine pancreatic peritoneal carcinomatosis with fibroblasts genetically modified to express IL12: a role for peritoneal innate immunity Gut, January 1, 2007; 56(1): 107 - 114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-S. Lee, J.-H. Kim, K.-J. Choi, I.-K. Choi, H. Kim, S. Cho, B. C. Cho, and C.-O. Yun Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and b7-1 in an immunocompetent murine model. Clin. Cancer Res., October 1, 2006; 12(19): 5859 - 5868. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Suzuki, T. Fukuhara, M. Tanaka, A. Nakamura, K. Akiyama, T. Sakakibara, D. Koinuma, T. Kikuchi, R. Tazawa, M. Maemondo, et al. Vaccination of Dendritic Cells Loaded with Interleukin-12-Secreting Cancer Cells Augments In vivo Antitumor Immunity: Characteristics of Syngeneic and Allogeneic Antigen-Presenting Cell Cancer Hybrid Cells Clin. Cancer Res., January 1, 2005; 11(1): 58 - 66. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-i. Yamashita, M. Shimada, R. Minagawa, E. Tsujita, N. Harimoto, S. Tanaka, K. Shirabe, J.-i. Miyazaki, and Y. Maehara Muscle-targeted interleukin-12 gene therapy of orthotopic hepatocellular carcinoma in mice using in vivo electrosonoporation Mol. Cancer Ther., September 1, 2004; 3(9): 1177 - 1182. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Tatsumi, J. Huang, W. E. Gooding, A. Gambotto, P. D. Robbins, N. L. Vujanovic, S. M. Alber, S. C. Watkins, H. Okada, and W. J. Storkus Intratumoral Delivery of Dendritic Cells Engineered to Secrete Both Interleukin (IL)-12 and IL-18 Effectively Treats Local and Distant Disease in Association with Broadly Reactive Tc1-type Immunity Cancer Res., October 1, 2003; 63(19): 6378 - 6386. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Nishioka, H. Wen, K. Mitani, P. D. Robbins, M. T. Lotze, S. Sone, and H. Tahara Differential effects of IL-12 on the generation of alloreactive CTL mediated by murine and human dendritic cells: a critical role for nitric oxide J. Leukoc. Biol., May 1, 2003; 73(5): 621 - 629. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Shi, A. L. Rakhmilevich, C. P. Heise, K. Oshikawa, P. M. Sondel, N.-S. Yang, and D. M. Mahvi Intratumoral Injection of Interleukin-12 Plasmid DNA, Either Naked or in Complex with Cationic Lipid, Results in Similar Tumor Regression in a Murine Model Mol. Cancer Ther., September 1, 2002; 1(11): 949 - 957. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Karnbach, M. R. Daws, E. C. Niemi, and M. C. Nakamura Immune Rejection of a Large Sarcoma Following Cyclophosphamide and IL-12 Treatment Requires Both NK and NK T Cells and Is Associated with the Induction of a Novel NK T Cell Population J. Immunol., September 1, 2001; 167(5): 2569 - 2576. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. S. Griffith, M. Kawakita, J. Tian, J. Ritchey, J. Tartaglia, I. Sehgal, T. C. Thompson, W. Zhao, and T. L. Ratliff Inhibition of Murine Prostate Tumor Growth and Activation of Immunoregulatory Cells With Recombinant Canarypox Viruses J Natl Cancer Inst, July 4, 2001; 93(13): 998 - 1007. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. DeGroot and R. Zhang CLINICAL REVIEW 131: Gene Therapy for Thyroid Cancer: Where Do We Stand? J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 2923 - 2928. [Full Text] [PDF]
|
|
|
|
|
|
Y.-i. Yamashita, M. Shimada, H. Hasegawa, R. Minagawa, T. Rikimaru, T. Hamatsu, S. Tanaka, K. Shirabe, J.-i. Miyazaki, and K. Sugimachi Electroporation-mediated Interleukin-12 Gene Therapy for Hepatocellular Carcinoma in the Mice Model Cancer Res., February 1, 2001; 61(3): 1005 - 1012. [Abstract] [Full Text]
|
|
|
|
|
|
S. Adris, E. Chuluyan, A. Bravo, M. Berenstein, S. Klein, M. Jasnis, C. Carbone, Y. Chernajovsky, and O. L. Podhajcer Mice Vaccination with Interleukin 12-transduced Colon Cancer Cells Potentiates Rejection of Syngeneic Non-Organ-related Tumor Cells Cancer Res., December 1, 2000; 60(23): 6696 - 6703. [Abstract] [Full Text]
|
|
|
|
|
|
C Lechanteur, P Delvenne, F Princen, M Lopez, G Fillet, J Gielen, M-P Merville, and V Bours Combined suicide and cytokine gene therapy for peritoneal carcinomatosis Gut, September 1, 2000; 47(3): 343 - 348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Mortarini, A. Borri, G. Tragni, I. Bersani, C. Vegetti, E. Bajetta, S. Pilotti, V. Cerundolo, and A. Anichini Peripheral Burst of Tumor-specific Cytotoxic T Lymphocytes and Infiltration of Metastatic Lesions by Memory CD8+ T Cells in Melanoma Patients Receiving Interleukin 12 Cancer Res., July 1, 2000; 60(13): 3559 - 3568. [Abstract] [Full Text]
|
|
|
|
|
|
M. Hirao, N. Onai, K. Hiroishi, S. C. Watkins, K. Matsushima, P. D. Robbins, M. T. Lotze, and H. Tahara CC Chemokine Receptor-7 on Dendritic Cells Is Induced after Interaction with Apoptotic Tumor Cells: Critical Role in Migration from the Tumor Site to Draining Lymph Nodes Cancer Res., April 1, 2000; 60(8): 2209 - 2217. [Abstract] [Full Text]
|
|
|
|
|
|
M. Stolina, S. Sharma, Y. Lin, M. Dohadwala, B. Gardner, J. Luo, L. Zhu, M. Kronenberg, P. W. Miller, J. Portanova, et al. Specific Inhibition of Cyclooxygenase 2 Restores Antitumor Reactivity by Altering the Balance of IL-10 and IL-12 Synthesis J. Immunol., January 1, 2000; 164(1): 361 - 370. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Schwarting, G. Tesch, K. Kinoshita, R. Maron, H. L. Weiner, and V. R. Kelley IL-12 Drives IFN-{gamma}-Dependent Autoimmune Kidney Disease in MRL-Faslpr Mice J. Immunol., December 15, 1999; 163(12): 6884 - 6891. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Dunussi-Joannopoulos, K. Runyon, J. Erickson, R. G. Schaub, R. G. Hawley, and J. P. Leonard Vaccines With Interleukin-12-Transduced Acute Myeloid Leukemia Cells Elicit Very Potent Therapeutic and Long-Lasting Protective Immunity Blood, December 15, 1999; 94(12): 4263 - 4273. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Jiang, D. M. Magee, and R. A. Cox Coadministration of Interleukin 12 Expression Vector with Antigen 2 cDNA Enhances Induction of Protective Immunity against Coccidioides immitis Infect. Immun., November 1, 1999; 67(11): 5848 - 5853. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Gee, C. J. Koch, S. M. Evans, W. T. Jenkins, C. H. Pletcher Jr., J. S. Moore, H. K. Koblish, J. Lee, E. M. Lord, G. Trinchieri, et al. Hypoxia-mediated Apoptosis from Angiogenesis Inhibition Underlies Tumor Control by Recombinant Interleukin 12 Cancer Res., October 1, 1999; 59(19): 4882 - 4889. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Hodge and J. Schlom Comparative Studies of a Retrovirus versus a Poxvirus Vector in Whole Tumor-Cell Vaccines Cancer Res., October 1, 1999; 59(20): 5106 - 5111. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Caminschi, E. Venetsanakos, C. C. Leong, M. J. Garlepp, B. W. S. Robinson, and B. Scott Cytokine Gene Therapy of Mesothelioma . Immune and Antitumor Effects of Transfected Interleukin-12 Am. J. Respir. Cell Mol. Biol., September 1, 1999; 21(3): 347 - 356. [Abstract] [Full Text]
|
|
|
|
|
|
M. Watanabe, R. G. Fenton, J. M. Wigginton, K. L. McCormick, K. M. Volker, W. E. Fogler, P. G. Roessler, and R. H. Wiltrout Intradermal Delivery of IL-12 Naked DNA Induces Systemic NK Cell Activation and Th1 Response In Vivo That Is Independent of Endogenous IL-12 Production J. Immunol., August 15, 1999; 163(4): 1943 - 1950. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Nishioka, M. Hirao, P. D. Robbins, M. T. Lotze, and H. Tahara Induction of Systemic and Therapeutic Antitumor Immunity Using Intratumoral Injection of Dendritic Cells Genetically Modified to Express Interleukin 12 Cancer Res., August 1, 1999; 59(16): 4035 - 4041. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Jiang, D. M. Magee, and R. A. Cox Construction of a Single-Chain Interleukin-12-Expressing Retroviral Vector and Its Application in Cytokine Gene Therapy against Experimental Coccidioidomycosis Infect. Immun., June 1, 1999; 67(6): 2996 - 3001. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. W. Mullins, C. J. Burger, and K. D. Elgert Paclitaxel Enhances Macrophage IL-12 Production in Tumor-Bearing Hosts Through Nitric Oxide J. Immunol., June 1, 1999; 162(11): 6811 - 6818. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Saleh, A. Wiegmans, Q. Malone, S. S. Stylli, and A. H. Kaye Effect of In Situ Retroviral Interleukin-4 Transfer on Established Intracranial Tumors J Natl Cancer Inst, March 3, 1999; 91(5): 438 - 445. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Robertson, C. Cameron, M. B. Atkins, M. S. Gordon, M. T. Lotze, M. L. Sherman, and J. Ritz Immunological Effects of Interleukin 12 Administered by Bolus Intravenous Injection to Patients with Cancer Clin. Cancer Res., January 1, 1999; 5(1): 9 - 16. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. C. Fernandez, J.-P. Levraud, H. Haddada, M. Perricaudet, and P. Kourilsky High Frequency of Specific CD8+ T Cells in the Tumor and Blood Is Associated with Efficient Local IL-12 Gene Therapy of Cancer J. Immunol., January 1, 1999; 162(1): 609 - 617. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-M. Peron, C. Esche, V. M. Subbotin, C. Maliszewski, M. T. Lotze, and M. R. Shurin FLT3-Ligand Administration Inhibits Liver Metastases: Role of NK Cells J. Immunol., December 1, 1998; 161(11): 6164 - 6170. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-M. Hu, W. J. Urba, and B. A. Fox Gene-Modified Tumor Vaccine with Therapeutic Potential Shifts Tumor-Specific T Cell Response from a Type 2 to a Type 1 Cytokine Profile J. Immunol., September 15, 1998; 161(6): 3033 - 3041. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. M. Siders, P. W. Wright, J. A. Hixon, W. G. Alvord, T. C. Back, R. H. Wiltrout, and R. G. Fenton T Cell- and NK Cell-Independent Inhibition of Hepatic Metastases by Systemic Administration of an IL-12-Expressing Recombinant Adenovirus J. Immunol., June 1, 1998; 160(11): 5465 - 5474. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Toda, R. L. Martuza, H. Kojima, and S. D. Rabkin In Situ Cancer Vaccination: An IL-12 Defective Vector/Replication-Competent Herpes Simplex Virus Combination Induces Local and Systemic Antitumor Activity J. Immunol., May 1, 1998; 160(9): 4457 - 4464. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. N. Lode, T. Dreier, R. Xiang, N. M. Varki, A. S. Kang, and R. A. Reisfeld Gene therapy with a single chain interleukin 12 fusion protein induces T cell-dependent protective immunity in a syngeneic model of murine neuroblastoma PNAS, March 3, 1998; 95(5): 2475 - 2480. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. M. Putzer, M. Hitt, W. J. Muller, P. Emtage, J. Gauldie, and F. L. Graham Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression PNAS, September 30, 1997; 94(20): 10889 - 10894. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Robertson and J. Ritz Interleukin 12: Basic Biology and Potential Applications in Cancer Treatment Oncologist, February 1, 1996; 1(1): 88 - 97. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. N. Parker, G. Y. Gillespie, C. E. Love, S. Randall, R. J. Whitley, and J. M. Markert From the Cover: Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors PNAS, February 29, 2000; 97(5): 2208 - 2213. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
